Evans School Policy Analysis & Research Group (EPAR)

The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.

This research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. We summarize the public good characteristics of R&D for agriculture in general and for commodity and subsistence crops in particular, as well as R&D for health in general and for neglected diseases in particular, with a focus on Sub-Saharan Africa and South Asia. Finally, we present rationales for which funders are predicted to fund which R&D types based on these funder and R&D characteristics. We then compile available statistics on funding for agricultural and health R&D from private, public and philanthropic sources, and compare trends in funding from these sources against expectations. We find private agricultural R&D spending focuses on commodity crops (as expected). However contrary to expectations we find public and philanthropic spending also goes largely towards these same crops rather than staples not targeted by private funds. For health R&D private funders similarly concentrate on diseases with higher potential financial returns. However unlike in agricultural R&D, in health R&D we observe some specialization across funders – especially for neglected diseases R&D - consistent with funders’ expected relative advantages.

This report reviews the current body of peer-reviewed scholarship exploring the impacts of morbidity on economic growth. This overview seeks to provide a concise introduction to the major theories and empirical evidence linking morbidity – and the myriad different measures of morbidity – to economic growth, which is defined primarily in terms of gross domestic product (GDP) and related metrics (wages, productivity, etc.). Through a systematic review of published manuscripts in the fields of health economics and economic development we further identify the most commonly-used pathways linking morbidity to economic growth. We also highlight the apparent gaps in the empirical literature (i.e., theorized pathways from morbidity to growth that remain relatively untested in the published empirical literature to date).

Cassava (Manihot esculenta Crantz) is a widely-grown staple food in the tropical and subtropical regions of Africa, Asia, and Latin America. In this brief we examine the environmental constraints to, and impacts of, smallholder cassava production systems in Sub-Saharan Africa (SSA) and South Asia (SA), noting where the analysis applies to only one of these regions. We highlight crop-environment interactions at three stages of the cassava value chain: pre-production (e.g., land clearing), production (e.g., soil, water, and input use), and post-production (e.g., crop storage). At each stage we emphasize environmental constraints on production (poor soil quality, water scarcity, crop pests, etc.) and also environmental impacts of crop production (e.g., soil erosion, water depletion and pesticide contamination). We then highlight good practices for overcoming environmental constraints and minimizing environmental impacts in smallholder cassava production systems. Evidence on environmental issues in smallholder cassava production is relatively thin, and unevenly distributed across regions. The literature on cassava in South Asian smallholder systems is limited, reflecting a crop of secondary importance (though it is widely found elsewhere in Asia such as South East Asia), in comparison to cassava in much of SSA. The majority of the research summarized in this brief is from SSA. The last row of Table 1 summarizes good practices currently identified in the literature. However, the appropriate strategy in a given situation will vary widely based on contextual factors, such as local environmental conditions, market access, cultural preferences, production practices and the policy environment.